Nov 22 (Reuters) - Halozyme Therapeutics Inc HALO.O:
HALOZYME WITHDRAWS PROPOSAL TO ACQUIRE EVOTEC FOLLOWING EVOTEC'S UNWILLINGNESS TO ENGAGE IN DISCUSSIONS
REITERATE RAISED 2024 GUIDANCE FOR REVENUE OF $970-$1,020 MILLION AND ADJUSTED EBITDA OF $595-$625 MILLION
TO DATE, EVOTEC HAS BEEN UNWILLING TO ENGAGE WITH US TO EXPLORE A POTENTIAL COMBINATION AND A COMPANY SPOKESPERSON HAS PUBLICLY COMMENTED THAT ITS GOAL IS TO REMAIN AN INDEPENDENT COMPANY
Source text: ID:nPn4cwbXMa
Further company coverage: EVTG.DE
(Gdansk Newsroom)
(((( gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.